The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...

Winter season can trigger symptoms of atopic dermatitis by causing the skin to become dry and itchy in the cold weather. It ...

Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients ...

A doctor can also review your treatment plan if existing dermatitis becomes widespread or isn’t getting better. Read on to learn more about the types and symptoms of dermatitis. This article ...

Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

Shaperon secures phase 2 trials for atopic dermatitis treatment Nugel after positive review Shaperon obtains approval for ...

Tofacitinib etocomil ointment 1.0% has proven effective in treating mild-to-moderate atopic dermatitis, achieving significant ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

Monthly tralokinumab is an effective dosing regimen for patients with atopic dermatitis who have achieved stable disease control.

Shaperon successfully completed part 1 of the multinational phase 2 clinical trial of 'HY209 gel' targeting patients with ...

Self-guided CBT for atopic dermatitis matches clinician-guided outcomes, easing clinical resource demands. Read now.

As we increase the number of patients, we remain excited by the outlook for our Phase 1 clinical trial of soquelitinib for ...